

MARKET NOTICE

Number: 212/2023

Relates to:

- Equity Market
- Equity Derivatives Market
- Commodity Derivatives Market
- Currency Derivatives Market
- Interest Rate Derivatives Market
- Bond Market
- Bond ETP Market

Date: 25 May 2023

SUBJECT: TREATMENT OF MEDICLINIC INT PLC (MEI) CORPORATE ACTION – CAPITAL PAYMENT WITH TERMINATION - 26 MAY 2023 (EX. DATE)

Name and Surname: Matthias Kempgen

Designation: Chief Information & Operating Officer – JSE Clear

Members notice is drawn to section 13 of the contract specifications of Individual Equity Futures and options, which states:

“13. Corporate Events

The JSE reserves the right to adopt any procedure or to adjust any single stock future or option on a single stock future, in a manner it deems fit, to deal with any extraordinary corporate events that may occur from time to time in relation to a share that is the underlying instrument of the equity option and to notify position holders, derivatives members and any other interested parties, of such event and the procedure or adjustment adopted. Such events include, for example, mergers, take-overs, unbundlings, capitalisation issues and rights issues.

The implication of this is that anybody trading in Single Stock futures or options on Single Stock futures in which the underlying stock is the subject of an extraordinary corporate event should be aware that the JSE may make adjustments to the Single Stock futures and options.

Capital Payment with Termination

MEDICLINIC INT PLC (MEI) has declared a capital payment of 11 910.5235 cents per share. With regards to this corporate action, the following adjustments will be made to MEI positions on 26 May 2023 (**Ex-date**). The adjustments will be made to the positions held as at close of business on 25 May 2023 (**LDT**).

Existing futures positions will be closed out at a fair value price determined on 25 May 2023 (**LDT**). All contracts with (MEI) as an underlying will be terminated on 26 May 2023 (Ex-date).

Please note:

Adjustments will be made to all contracts where MEI is the underlying share. These contracts include:

Contract Code	JSE Instrument Type
15JUN23 MEI PHY DN	Dividend Neutral
15JUN23 MEI PHY CA1	Single Stock
15JUN23 MEI PHY DN CA1	Dividend Neutral
15JUN23 MEI CSH	Single Stock
15JUN23 MEI PHY	Single Stock
21SEP23 MEI PHY DN	Dividend Neutral
21SEP23 MEI PHY CA1	Single Stock
21SEP23 MEI PHY DN CA1	Dividend Neutral
21SEP23 MEI CSH	Single Stock
21SEP23 MEI PHY	Single Stock
21DEC23 MEI PHY DN	Dividend Neutral
21DEC23 MEI PHY CA1	Single Stock
21DEC23 MEI PHY DN CA1	Dividend Neutral
21DEC23 MEI CSH	Single Stock
21DEC23 MEI PHY	Single Stock
20MAR24 MEI PHY DN	Dividend Neutral
20MAR24 MEI PHY CA1	Single Stock
20MAR24 MEI PHY DN CA1	Dividend Neutral
20MAR24 MEI CSH CFD RODI	CFD
20MAR24 MEI CSH CFD SABOR	CFD
20MAR24 MEI CSH	Single Stock
20MAR24 MEI PHY	Single Stock

TREATMENT FOR ALLOCATION ON ADDITIONAL CONTRACTS

With the implementation of ITaC, the JSE has enhanced the position adjustment process.

Please see link below to the Guidance Note issued on treatment of corporate actions as distributed in October 2018 and specifically refer to Section 8 for details of the position adjustment process:

<https://www.jse.co.za/content/Guidance%20Notes/ITaC%20Guidance%20Note%20on%20Corporate%20Actions.pdf>

Should you have any queries regarding this Market Notice, please e-mail: clearops@jse.co.za

This Market Notice is available on the JSE website at: [JSE Market Notices](#)